Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
暂无分享,去创建一个
M. Lichinitser | G. Jerusalem | Miguel Martín | A. Di Leo | Sally Garnett | I. Bondarenko | J. Lindemann | K. Pendergrass | D. Verhoeven | R. Torres | R. Khasanov | I. Smirnova | J. Pedrini | F. Sapunar | L. Petruželka
[1] Chia-Jung Lu,et al. Development of a Novel , 2011 .
[2] D. Jeffe,et al. A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. , 2009 .
[3] V. Jordan. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] N. Harbeck,et al. NEWEST: a Phase II, randomised, neoadjuvant trial comparing fulvestrant 500 mg vs 250 mg in postmenopausal women with locally advanced, oestrogen receptor-positive (ER+) breast cancer , 2008 .
[5] P. Lønning,et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy , 2001, Breast Cancer Research and Treatment.
[6] L. Hartmann,et al. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis , 1999, Breast Cancer Research and Treatment.
[7] Hong Liu,et al. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. , 2003, Journal of the National Cancer Institute.
[8] M. Ellis,et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women , 2003, Cancer.
[9] Gottfried Konecny,et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.
[10] A. Howell,et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C K Osborne,et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Dowsett,et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. , 2001, Cancer research.
[13] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[14] A. Howell,et al. ICI 182,780 (Faslodex™) , 2000, Cancer.
[15] A. Howell,et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. , 1994, Cancer research.
[16] A. Wakeling,et al. A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.